
    
      Screening Phase: It will begin when informed consent form (ICF) is signed and be a maximum of
      14 days, to evaluate the inclusion/exclusion criteria, collect information such as
      demographic data, medical history, wash out previous antipsychotic agents and other
      prohibited concomitant medications.

      Double-blind Treatment Phase: It lasts 6 weeks; the purpose is to compare the efficacy and
      safety of Brexpiprazole with Aripiprazole in the treatment of adults with acute
      schizophrenia.

      Follow-up Phase: All subjects will be followed up for safety reasons via telephone contact or
      clinic visit 30 (+ 2) days after the last dose of investigational medicinal product,
      collecting safety information (adverse events and concomitant medication).
    
  